180 related articles for article (PubMed ID: 20705615)
1. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.
Wittenburg LA; Gustafson DL; Thamm DH
Clin Cancer Res; 2010 Oct; 16(19):4832-42. PubMed ID: 20705615
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
Wittenburg LA; Bisson L; Rose BJ; Korch C; Thamm DH
Cancer Chemother Pharmacol; 2011 Jan; 67(1):83-92. PubMed ID: 20306194
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Wheler JJ; Janku F; Falchook GS; Jackson TL; Fu S; Naing A; Tsimberidou AM; Moulder SL; Hong DS; Yang H; Piha-Paul SA; Atkins JT; Garcia-Manero G; Kurzrock R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):495-501. PubMed ID: 24435060
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
7. A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.
Tarasenko N; Cutts SM; Phillips DR; Berkovitch-Luria G; Bardugo-Nissim E; Weitman M; Nudelman A; Rephaeli A
Biochem Pharmacol; 2014 Mar; 88(2):158-68. PubMed ID: 24463168
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors.
Hauck ML; LaRue SM; Petros WP; Poulson JM; Yu D; Spasojevic I; Pruitt AF; Klein A; Case B; Thrall DE; Needham D; Dewhirst MW
Clin Cancer Res; 2006 Jul; 12(13):4004-10. PubMed ID: 16818699
[TBL] [Abstract][Full Text] [Related]
9. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Scherpereel A; Berghmans T; Lafitte JJ; Colinet B; Richez M; Bonduelle Y; Meert AP; Dhalluin X; Leclercq N; Paesmans M; Willems L; Sculier JP;
Eur Respir J; 2011 Jan; 37(1):129-35. PubMed ID: 20530048
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
de Jong FA; van der Bol JM; Mathijssen RH; Loos WJ; Mathôt RA; Kitzen JJ; van den Bent MJ; Verweij J
Cancer Biol Ther; 2007 Sep; 6(9):1368-74. PubMed ID: 17873515
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.
Marley K; Helfand SC; Simpson J; Mata JE; Tracewell WG; Brownlee L; Bracha S; Séguin B
J Exp Clin Cancer Res; 2013 Oct; 32(1):74. PubMed ID: 24422857
[TBL] [Abstract][Full Text] [Related]
14. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.
Uitrakul S; Hutton C; Veal GJ; Jamieson D
Eur J Clin Invest; 2019 Jul; 49(7):e13115. PubMed ID: 30929275
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.
Kosarek CE; Hu X; Couto CG; Kisseberth WC; Green EM; Au JL; Wientjes MG
J Vet Intern Med; 2006; 20(5):1172-7. PubMed ID: 17063712
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
Georgoff PE; Nikolian VC; Bonham T; Pai MP; Tafatia C; Halaweish I; To K; Watcharotone K; Parameswaran A; Luo R; Sun D; Alam HB
Clin Pharmacokinet; 2018 Feb; 57(2):209-219. PubMed ID: 28497259
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.
Barnard RA; Wittenburg LA; Amaravadi RK; Gustafson DL; Thorburn A; Thamm DH
Autophagy; 2014 Aug; 10(8):1415-25. PubMed ID: 24991836
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner LA; Laughlin A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Br J Cancer; 2011 Mar; 104(5):756-62. PubMed ID: 21285985
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Munster PN; Marchion D; Thomas S; Egorin M; Minton S; Springett G; Lee JH; Simon G; Chiappori A; Sullivan D; Daud A
Br J Cancer; 2009 Oct; 101(7):1044-50. PubMed ID: 19738609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
